Chong Kun Dang Pharmaceutical Corp.

KOSE:A185750 Stock Report

Market Cap: ₩1.2t

Chong Kun Dang Pharmaceutical Valuation

Is A185750 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A185750 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₩206.42k
Fair Value
55.9% undervalued intrinsic discount
7
Number of Analysts

Below Fair Value: A185750 (₩91000) is trading below our estimate of fair value (₩206418.3)

Significantly Below Fair Value: A185750 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A185750?

Key metric: As A185750 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A185750. This is calculated by dividing A185750's market cap by their current earnings.
What is A185750's PE Ratio?
PE Ratio6.4x
Earnings₩189.04b
Market Cap₩1.21t

Price to Earnings Ratio vs Peers

How does A185750's PE Ratio compare to its peers?

The above table shows the PE ratio for A185750 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18.7x
A214370 Caregen
39.4x25.6%₩1.4t
A069620 Daewoong Pharmaceutical
14.4x13.7%₩1.5t
A003090 Daewoong
6.8xn/a₩840.3b
A003850 Boryung
14x12.1%₩869.9b
A185750 Chong Kun Dang Pharmaceutical
6.4x-15.2%₩1.2t

Price-To-Earnings vs Peers: A185750 is good value based on its Price-To-Earnings Ratio (6.4x) compared to the peer average (18.7x).

Price to Earnings Ratio vs Industry

How does A185750's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
A185750 6.4xIndustry Avg. 13.4xNo. of Companies9PE01020304050+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A185750 is good value based on its Price-To-Earnings Ratio (6.4x) compared to the KR Pharmaceuticals industry average (13.4x).

Price to Earnings Ratio vs Fair Ratio

What is A185750's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A185750 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.4x
Fair PE Ratio11.3x

Price-To-Earnings vs Fair Ratio: A185750 is good value based on its Price-To-Earnings Ratio (6.4x) compared to the estimated Fair Price-To-Earnings Ratio (11.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A185750 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩91,000.00
₩143,823.13
+58.0%
3.2%₩152,380.95₩136,190.48n/a7
Jan ’26₩89,000.00
₩147,142.86
+65.3%
6.9%₩171,428.57₩136,190.48n/a8
Dec ’25₩90,190.48
₩147,142.86
+63.1%
6.9%₩171,428.57₩136,190.48n/a8
Nov ’25₩95,619.05
₩147,142.86
+53.9%
6.9%₩171,428.57₩136,190.48n/a8
Oct ’25₩107,047.62
₩147,142.86
+37.5%
6.9%₩171,428.57₩136,190.48n/a8
Sep ’25₩118,476.19
₩147,142.86
+24.2%
6.9%₩171,428.57₩136,190.48n/a8
Aug ’25₩108,476.19
₩145,079.37
+33.7%
7.7%₩171,428.57₩128,571.43n/a9
Jul ’25₩92,952.38
₩145,079.37
+56.1%
7.7%₩171,428.57₩128,571.43n/a9
Jun ’25₩99,523.81
₩145,079.37
+45.8%
7.7%₩171,428.57₩128,571.43n/a9
May ’25₩99,333.33
₩145,079.37
+46.1%
7.7%₩171,428.57₩128,571.43n/a9
Apr ’25₩106,000.00
₩145,079.37
+36.9%
7.7%₩171,428.57₩128,571.43n/a9
Mar ’25₩103,047.62
₩145,340.14
+41.0%
8.2%₩171,428.57₩128,571.43n/a8
Feb ’25₩101,904.76
₩141,184.81
+38.5%
5.4%₩152,380.95₩128,571.43n/a8
Jan ’25₩124,666.67
₩129,251.70
+3.7%
13.4%₩145,124.72₩99,773.24₩89,000.008
Dec ’24₩112,834.47
₩112,730.81
-0.09%
14.2%₩136,054.42₩99,773.24₩90,190.487
Nov ’24₩85,804.99
₩101,069.00
+17.8%
7.5%₩117,913.83₩90,702.95₩95,619.057
Oct ’24₩85,079.37
₩95,885.97
+12.7%
4.7%₩99,773.24₩90,702.95₩107,047.627
Sep ’24₩76,553.29
₩95,885.97
+25.3%
4.7%₩99,773.24₩90,702.95₩118,476.197
Aug ’24₩72,108.84
₩99,773.24
+38.4%
9.1%₩117,913.83₩90,702.95₩108,476.198
Jul ’24₩74,467.12
₩103,174.60
+38.6%
8.7%₩117,913.83₩90,702.95₩92,952.388
Jun ’24₩80,000.00
₩103,174.60
+29.0%
8.7%₩117,913.83₩90,702.95₩99,523.818
May ’24₩76,825.40
₩103,714.50
+35.0%
8.0%₩117,913.83₩90,702.95₩99,333.338
Apr ’24₩70,385.49
₩104,092.43
+47.9%
8.4%₩117,913.83₩90,702.95₩106,000.008
Mar ’24₩71,746.03
₩101,452.93
+41.4%
10.9%₩117,913.83₩80,336.90₩103,047.629
Feb ’24₩73,832.20
₩100,301.14
+35.9%
10.5%₩117,913.83₩80,336.90₩101,904.769
Jan ’24₩74,467.12
₩99,629.27
+33.8%
9.4%₩112,298.89₩80,336.90₩124,666.679
Analyst Price Target
Consensus Narrative from 7 Analysts
₩143.82k
Fair Value
36.7% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 02:28
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chong Kun Dang Pharmaceutical Corp. is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyerin LeeDAOL Investment & Securities Co., Ltd.
Jisoo LeeDAOL Investment & Securities Co., Ltd.
null nullDBS Bank Ltd